Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial (Q45369180)
Jump to navigation
Jump to search
scientific article published on 5 November 2012
Language | Label | Description | Also known as |
---|---|---|---|
English | Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial |
scientific article published on 5 November 2012 |
Statements
1 reference
Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial (English)
1 reference
Peter Libby
1 reference
Paul M Ridker
1 reference
Tom Thuren
1 reference
Campbell P Howard
1 reference
Verena Walter
1 reference
Brendan Everett
1 reference
Johannes Hensen
1 reference
CANTOS Pilot Investigative Group
1 reference
5 November 2012
1 reference
1 reference
126
1 reference
23
1 reference
2739-2748
1 reference
Identifiers
1 reference
1 reference